- Trials with a EudraCT protocol (27)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
27 result(s) found for: Zofran.
Displaying page 1 of 2.
EudraCT Number: 2008-004789-20 | Sponsor Protocol Number: GDW07/08 | Start Date*: 2008-09-05 |
Sponsor Name:UZLEUVEN | ||
Full Title: ” A comparative double-blind placebo-controlled study between alizapride and ondansetron for the prevention of postoperative nausea and vomiting.” | ||
Medical condition: Prevention of post-operative nausea and vomiting. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-005855-16 | Sponsor Protocol Number: NKT102552 | Start Date*: 2006-03-20 |
Sponsor Name:GlaxoSmithKline Research and Development Ltd | ||
Full Title: A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for... | ||
Medical condition: Postoperative Nausea and Vomiting (PONV) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: BE (Completed) HU (Completed) ES (Completed) CZ (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-005700-15 | Sponsor Protocol Number: marha1983 | Start Date*: 2013-01-07 |
Sponsor Name:Lennart Svensson Linköping University Medical Faculty | ||
Full Title: Can 5-HT3 receptor antagonists be used to limit vomiting in rota- and norovirus infections? | ||
Medical condition: Virus caused vomiting and effect of the antiemetic drug Ondansetron | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-002033-21 | Sponsor Protocol Number: NKV102551 | Start Date*: 2006-09-11 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Ltd | |||||||||||||
Full Title: A Phase III Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group Study of the Efficacy and Safety of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonis... | |||||||||||||
Medical condition: Chemotherapy induced nausea and vomiting (CINV) due to Highly Emetogenic Chemotherapy (HEC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) ES (Completed) IE (Completed) GR (Completed) BE (Completed) CZ (Completed) SK (Completed) HU (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005856-42 | Sponsor Protocol Number: NKT102553 | Start Date*: 2006-03-29 |
Sponsor Name:GlaxoSmithKline Research and Development Ltd | ||
Full Title: A Phase III, Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of 50 mg Oral Dosing with the Neurokinin-1 Receptor Antagonist GW679769 for the Preventi... | ||
Medical condition: Postoperative Nausea and Vomiting (PONV) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: GB (Completed) HU (Completed) DE (Completed) IE (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-000781-37 | Sponsor Protocol Number: NKV102549 | Start Date*: 2006-07-24 |
Sponsor Name:GlaxoSmithKline Research and Development Ltd | ||
Full Title: A Phase III, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group Study of the Safety and Efficacy of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagon... | ||
Medical condition: Chemotherapy induced nausea and vomiting (CINV) due to Moderately Emetogenic Chemotherapy (MEC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) DE (Completed) BE (Completed) IE (Completed) SK (Completed) ES (Completed) AT (Completed) EE (Completed) CZ (Completed) LT (Completed) HU (Completed) DK (Completed) LV (Completed) GR (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-000370-31 | Sponsor Protocol Number: NKT102260 | Start Date*: 2005-05-20 |
Sponsor Name:GlaxoSmithKline Group of Companies | ||
Full Title: A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of the Oral Neurokinin-1 Receptor Ant... | ||
Medical condition: Post Operative Nausea and Vomiting (PONV) Post Discharge Nausea and Vomiting (PDNV) | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: HU (Completed) BE (Completed) DE (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-001021-22 | Sponsor Protocol Number: NKO101287 | Start Date*: 2005-02-08 |
Sponsor Name:GlaxoSmithKline Research and Development Limited | ||
Full Title: A Multicentre, Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel Group, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Oral (25 mg) and Intravenous (3 m... | ||
Medical condition: Post Operative Nausea and Vomiting (PONV) Post Discharge Nausea and Vomiting (PDNV) | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: FI (Completed) CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-003512-22 | Sponsor Protocol Number: 0869-130 | Start Date*: 2006-11-23 |
Sponsor Name:Laboratoires Merck Sharp & Dohme-Chibret | ||
Full Title: A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nau... | ||
Medical condition: Chemotherapy-induced Nausea and Vomitting | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-000369-37 | Sponsor Protocol Number: NKT102245 | Start Date*: 2005-02-01 |
Sponsor Name:GlaxoSmithKline Group of Companies | ||
Full Title: A multicentre, randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of oral dosing with GW679769 (50 mg or 150 mg) for 3 consecutive days in conjun... | ||
Medical condition: Post Operative Nausea and Vomiting (PONV) Post Discharge Nausea and Vomiting (PDNV) | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: HU (Completed) GB (Completed) ES (Completed) DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-003178-17 | Sponsor Protocol Number: 0869-148 | Start Date*: 2009-01-19 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: Estudio multicéntrico de 2 partes para evaluar la farmacocinética, la seguridad y la tolerabilidad del aprepitant en pacientes pediátricos sometidos a una intervención quirúrgica. A Multicenter, 2-... | |||||||||||||
Medical condition: Prevención de nauseas y vómitos postoperatorios en pacientes pediátricos. Prevention of Postoperative nausea and vomiting in pediatric patients. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) FI (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001020-20 | Sponsor Protocol Number: NKV101983 | Start Date*: 2005-01-25 |
Sponsor Name:GlaxoSmithKline Group of Companies | ||
Full Title: | ||
Medical condition: Chemotherapy Induced Nausea and Vomiting (CINV) 0 Moderately Emetogenic Chemotherapy (MEC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) IE (Completed) SK (Completed) HU (Completed) AT (Completed) GB (Completed) DE (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-004603-78 | Sponsor Protocol Number: MK-0869-097-02 | Start Date*: 2015-02-13 |
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | ||
Full Title: A Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of Aprepitant for the Preventio... | ||
Medical condition: chemotherapy induced nausea and vomiting | ||
Disease: | ||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2006-001761-42 | Sponsor Protocol Number: 0869-131 | Start Date*: 2006-06-12 | |||||||||||
Sponsor Name:Merck & Co., Inc | |||||||||||||
Full Title: A Randomized, Double-Blind, Active Comparator-Controlled, Parallel-Group Study Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of Aprepitant for the ... | |||||||||||||
Medical condition: Postoperative Nausea and Vomiting | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Prematurely Ended) AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000371-34 | Sponsor Protocol Number: NKV20001 | Start Date*: 2005-01-25 |
Sponsor Name:GlaxoSmithKline Group of Companies | ||
Full Title: A Phase II Multicentre, Randomised, Double-Blind, Placebo and Active-Controlled, Dose-Ranging, Parallel Group Study of the Safety and Efficacy of The Oral Neurokinin-1 Receptor Antagonist, GW679769... | ||
Medical condition: Chemotherapy-Induced Nausea and Vomiting (CINV) - Highly Emetogenic Chemotherapy (HEC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) SK (Completed) AT (Completed) HU (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-001718-41 | Sponsor Protocol Number: 0517-31 | Start Date*: 2012-09-04 |
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | ||
Full Title: A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of... | ||
Medical condition: chemotherapy induced nausea and vomiting | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) NL (Completed) ES (Completed) CZ (Completed) SE (Completed) HU (Completed) IT (Completed) PT (Completed) LV (Completed) PL (Completed) BG (Completed) GR (Completed) NO (Completed) HR (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-002343-16 | Sponsor Protocol Number: 1014/05 | Start Date*: 2006-01-05 | |||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
Full Title: Postoperative nausea and vomiting: acupuncture effect on postoperative prevention | |||||||||||||
Medical condition: Postoperative nausea and vomiting laparoscopic cholecistectomy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002340-24 | Sponsor Protocol Number: 0517-029 | Start Date*: 2012-10-26 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase IIb, Partially-Blinded, Randomized, Active Comparator-Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Fosaprepitant in Pediatric Patients for... | |||||||||||||
Medical condition: Chemotherapy-induced nausea and vomiting (CINV) associated with emetogenic chemotherapy | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) PT (Completed) DE (Completed) AT (Completed) HU (Completed) EE (Completed) GB (Completed) LT (Completed) GR (Completed) IT (Completed) RO (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-006006-27 | Sponsor Protocol Number: 0869-219 | Start Date*: 2012-11-05 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc | |||||||||||||
Full Title: A Phase IIb, Partially-Blinded, Randomized, Active Comparator-Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Aprepitant in Pediatric Patients for th... | |||||||||||||
Medical condition: Post Operative Nausea and Vomiting in surgical patients | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) ES (Completed) CZ (Completed) IT (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005311-25 | Sponsor Protocol Number: 222222 | Start Date*: 2007-11-09 | ||||||||||||||||
Sponsor Name:Ritva Jokela | ||||||||||||||||||
Full Title: Ondansetronin vaikutus parasetamolin kipulääkevasteeseen tähystyksen kautta tehtävän kohdunpoiston yhteydessä | ||||||||||||||||||
Medical condition: Tähystysleikkauksen jälkeinen kipu | ||||||||||||||||||
|
||||||||||||||||||
Population Age: | Gender: Female | |||||||||||||||||
Trial protocol: FI (Completed) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.